NCT03947229View on ClinicalTrials.gov

A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

3,200

Participants

Timeline

Start Date

August 14, 2019

Primary Completion Date

August 16, 2025

Study Completion Date

August 16, 2026

Conditions
Coronary Artery DiseaseDES
Interventions
DRUG

Clopidogrel mono-therapy

Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.

DRUG

Dual-antiplatelet therapy

Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.

Trial Locations (1)

Unknown

Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu 120-752 Seoul, South Korea, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER